Business
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabo
About this update from Aardvark Therapeutics, Inc.
[{"type":"image","alt":"Aardvark Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Aardvark Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/fe55bd926bdb60296161677c87a21101"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uwJDwhhUtlawg8Ki3jqHIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4/https://media.zenfs.com/en/globenewswire.com/fe55bd926bdb60296161677c87a21101","width":300,"height":63}},"lazy":false},{"type":"text","content":"ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026","length":85,"tagName":"p"},{"type":"text","content":"$91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027","length":132,"tagName":"p"},{"type":"text","content":"SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 31, 2026, and provided pipeline and business updates.","length":415,"tagName":"p"},{"type":"text","content":"“We have been working closely with the FDA to comprehensively evaluate the data following the reversible cardiac observations in the healthy volunteer trial and are committed to determining the best path forward for our programs, patients and the broader PWS community,” said Tien Lee, M.D., Founder and Chief Executive Officer of Aardvark. “We remain focused on establishing a clear path forward for the Phase 3 HERO trial evaluating ARD-101 in PWS, our lead program, and look forward to providing an update in the second quarter.”","length":532,"tagName":"p"},{"type":"text","content":"Pipeline Updates","length":16,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In February 2026, the Company announced a voluntary pause in enrollment and dosing in the Phase 3 Hunger Elimination or Reduction Objective (HERO) and open-label extension (OLE) trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome (PWS) following unexpected reversible cardiac observations in a separ...